Archive for August, 2021
Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) is a multistate cannabis operator and house of premium brands. The company has announced the schedule for release of its second-quarter 2021 financial results. According to the update, RWB will be releasing Q2 2021 financial statements, accompanying notes and MD&A after market close on Monday, Aug. 30, 2021.
To view the full press release, visit https://ibn.fm/tru6w
About Red White & Bloom Brands Inc.
The company is positioning itself to be one of the top three multistate cannabis operators active in the U.S. legal cannabis and hemp sector. RWB is predominantly focusing its investments on the major U.S. markets, including Michigan, Illinois, Florida, Oklahoma, Arizona, and California with respect to cannabis, and the U.S. and internationally for hemp-based CBD products. For more information about the company, visit www.RedWhiteBloom.com.
NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at http://ibn.fm/RWBYF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork
PBI Agrochem Integration into the Sales Channels of Its Planned Asset Acquisition of a Global, Environmentally Responsible Agrochem Company is Expected to Result in a Significant Q3 2021 Impact
SOUTH EASTON, MA / August 12, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food & beverage industries, today announced that its newly-formed agrochemicals subsidiary – PBI Agrochem, Inc. – has received initial purchase orders for over $1M of eco-friendly agrochemical products for delivery in 2021. Just three weeks ago, the Company announced the formation of its new agrochemicals division in anticipation of the planned asset acquisition of a global agrochemicals products business focused on organically natural and environmentally responsible products.
PBI’s President and CEO Richard T. Schumacher explained the fast development of early sales: “With integration planning for this acquisition well underway, PBI Agrochem placed an initial order for specialized, proprietary bulk material in July and began establishing U.S. warehousing, processing, and final product packaging facilities. Our objective was to insert PBI Agrochem into the supply chain and sales channels of our acquisition target, in order to capture early sales revenues that we believe could have an immediate, accretive impact upon PBI’s overall operating results. These efforts have resulted in over $1M in 2021 customer orders for eco-friendly and effective agrochemical pest control and growth stimulant products.”
Mr. Schumacher continued: “We anticipate that the delivery and booking for most of these orders will occur during the third quarter 2021. PBI investors who have followed and supported the Company through recent years understand that this new incremental revenue from PBI Agrochem represents a potential doubling (or more) of quarterly revenues, when added to sales of PBI’s existing core products and services. With additional orders expected to arrive over the coming weeks and months, we believe Q4 2021 could substantially exceed the results of Q3 2021. Our new agrochem sales are expected to accelerate PBI’s rapidly improving growth trajectory and should contribute substantially towards our planned transition to profitability by the end of 2022.”
Mr. John B. Hollister, Director of Sales and Marketing at PBI, said: “The market potential in agrochemicals is enormous, driven by the intersection of burgeoning global population growth and accelerating environmental consciousness and priorities. Our positioning in organically natural and ecofriendly product solutions places PBI squarely within the hottest growth generation in this sector. Closing on over $1M of orders in the first month of PBI Agrochem operations is a welcome signpost on the road to major growth and profitability for our agrochem operations. The broad array of eco-friendly products being integrated into PBI will address a diversity of agrochem client needs throughout the year, from fertilizing young plants, to mitigating microbial and larger animal threats, to enhancing the appearance and appeal of finished produce.”
PBI’s Board Chairman Jeffrey N. Peterson commented on the synergies achieved in PBI’s move into agrochemicals: “The creation of many organically natural and effective, environmentally-friendly agrochemical products is typically achieved through utilization of essential oil active ingredients extracted from plants, such as the already popular use of orange peel essential oil in ant sprays. PBI’s breakthrough Ultra Shear Technology™ (UST™) platform, for creation of extremely low-droplet size nanoemulsions of oils in water, offers added value for a new generation of products with improved effectiveness and economics, allowing less active material to deliver higher effectiveness when applied or consumed. We are aggressively driving the creation of pioneering partnerships around UST in application sectors from pharmaceuticals to nutraceuticals to food/beverage and many more areas, as PBI’s core strategy for growth and profitability. We have singled out agrochemicals for a more aggressive forward integration into an applications sector for UST, in a bid to accelerate the cycle of education, trial, market demonstration, product differentiation, and uniquely advantaged growth. We are delighted to be sharing these insights into PBI’s expected accelerating growth trajectory and path to profitability with our loyal investor base.”
The asset acquisition is subject to certain conditions, including the completion of all due diligence and acquisition financing.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB:PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter.
Press Contacts:
Richard T. Schumacher, President & CEO, (508) 230-1828 (T)
John B. Hollister, Director of Sales and Marketing, (508) 230-1828 (T)
Jeffrey N. Peterson, Chairman, (650) 703-8557 (T)
Recently conducted research has discovered that cervical cancer can be detected by clinicians using a handheld microscope and a topical fluorescent imaging agent dubbed PARPi-FL. This imaging technique targets the PARP1 enzyme, which is overexpressed in this type of cancer. It has the potential to revolutionize cervical cancer biopsies and screenings.
Cervical cancer is the fourth most common cancer in women. Data shows that in 2018, nearly 600,000 women were diagnosed with this cancer type globally, with roughly 310,000 of them succumbing to the disease.
Almost 99% of cervical cancer cases are caused by human papilloma virus (“HPV”), which can remain dormant in the female body for years before cervical cells begin to turn cancerous. HPV is an extremely common virus that is transmitted through sexual contact. There are high-risk and low-risk HPV infections. Most infections cause no symptoms and resolve on their own, while some infections cause cervical cancer to develop.
This type of cancer still has a high prevalence rate around the world, despite efforts in ailment prevention with screening programs and HPV vaccinations. HPV vaccines have been developed to prevent almost all of the infection’s strains. However, cervical cancer remains a huge issue in public health, particularly in low-resource areas where HPV prevalence is high.
Elizabeth Jewell, an attending physician on gynecologic oncology, stated that cervical cancer was a clinical problem that could be avoided by a noninvasive, in-vivo and cost-effective diagnosis technique.
The researchers conducted cervical biopsies from human and animal models in which PARP1 enzyme expression was evaluated. The cervical cells were stained with the fluorescent imaging agent and observed using a handheld confocal fiber optic microscope. The researchers also conducted an analysis of PARP1 expression in cells extracted from the cervix as well as histological exams to verify the enzyme’s presence.
They found that in comparison to normal surrounding tissue, the fluorescent imaging agent demonstrated higher uptake in lesions, which correlated with PARP1 expression in the area. The tumor cells also demonstrated a disorganized pattern, which was easy to discern through the use of PARPi-FL.
Visiting MSK investigator Paula Demetrio de Souza Franca noted that examining lesions using this approach was painless, safe and noninvasive, and could possibly be used to accurately diagnose various types of cancer like cervical cancer, as well as manage their treatment. She added that the fluorescent imaging agent could also be used in the identification of cancer cells during colposcopy procedures as well as play the role of a more accurate guide for biopsies and maybe even do away with biopsies.
The study was published in the “Journal of Nuclear Medicine.”
A lot of investment is being directed towards studying cancer because it is a global challenge impacting significant numbers of people. However, since cancer occurs in various forms, it has often been problematic to diagnose some forms early enough, and that may be why companies such as Predictive Oncology (NASDAQ: POAI) are focused on harnessing the power of data analytics and AI to improve diagnosis within the global oncology sector.
NOTE TO INVESTORS: The latest news and updates relating to Predictive Oncology (NASDAQ: POAI) are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
As the United Kingdom deals with record floods and extreme heat, it is becoming increasingly clear that climate change is an issue that needs swift action. The UK’s plan of action involves replacing conventional internal combustion engine (“ICE”) vehicles with zero-emission electric vehicles (“EVs”), with the aim of eliminating the sale of new ICE vehicles by 2030. While it is an ambitious goal that could have significant benefits in the long run, EV adoption is still quite low.
A lot of experts and drivers agree that range anxiety has been a significant hindrance to EV adoption. To alleviate this issue, the government has dedicated most of its efforts toward developing a network of public charging stations. However, a new study has found that focusing on home charging infrastructure, especially for individuals without off street parking, would be a much better remedy for range anxiety. Since cars spend a majority of their lifetimes (at least 90%) parked outside their owners’ homes, investing in home chargers is a great way to address deficiencies in EV charging infrastructure.
According to official figures, 18 million to 27.6 million (65%) of British households have, or have the potential to have, enough street parking space for at least one vehicle, either passenger car or van. For the past 20 or so years, the average British vehicle has been on the road for only 4% of its lifetime, says the RAC Foundation, with the rest of the time spent parked either at home (73%) or somewhere else, typically at work (23%). For the 35% of drivers who live in homes that do not have access to off street parking, local authorities will have to find ways to provide home charging infrastructure to encourage them to switch to electric cars.
Regardless of the hurdles such a project will face, this presents a huge opportunity for charging electric vehicles as they become more accessible, says the RAC Foundation. The foundation’s director Steve Gooding says taking advantage of the cars’ “downtime” when they are parked rather than relying on public chargers would also come with cost savings.
Since the vehicle would be parked at home for hours at a time anyway, installing slower, cheaper chargers would be a feasible option. With English drivers consistently driving an average of 1 out of 24 hours since 1995, there would be plenty of time for drivers to charge their EVs, and if drivers only use their vehicles to go to work and run errands, a single charge would probably last at least a couple of days.
The government has invested plenty of resources into developing public charging infrastructure. Such a network would undoubtedly be a godsend for long-distance drivers, but focusing on home chargers would be a much better way of addressing range anxiety and making EV charging more accessible.
Plenty of outside-the-box thinking will be needed to convince more motorists to switch to electrified transport, and the entry of entities such as Net Element (NASDAQ: NETE) into the EV space may provide the fresh pair of eyes needed to spot a solution that will touch the hearts and minds of the motoring public.
NOTE TO INVESTORS: The latest news and updates relating to Net Element (NASDAQ: NETE) are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, today announced its plans to participate at the upcoming H.C. Wainwright Ophthalmology Virtual Conference. According to the update, InMed’s CEO and President Eric. A. Adams and SVP of Pre-Clinical Research and Development Dr. Eric Hsu will present at the conference on Tuesday, Aug. 17, 2021. Adams and Dr. Hsu will provide an overview of the company’s ocular program, including INM-088, a topical eye drop formulation under development for the treatment of glaucoma. INM-088’s active pharmaceutical ingredient (“API”) is cannabinol, also known as CBN, a rare cannabinoid showing promise in its potential to provide neuroprotection and to reduce intraocular pressure of the eye. The on-demand presentation will be available at 7:00 a.m. ET on Aug. 17, 2021, accessible from the HC Wainwrights events platform. An archived replay of the presentation will be available on InMed’s website immediately following the conference for 90 days.
To view the full press release, visit https://ibn.fm/1W2sS
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (“CBN”), and is developing IntegraSyn(TM) to produce pharmaceutical-grade cannabinoids. The company is dedicated to delivering new therapeutic alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at http://ibn.fm/INM
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Oslo, Norway – 12 August 2021 – IDEX Biometrics ASA (IDEX Biometrics or the Company), a leading provider of advanced fingerprint identification and authentication solutions for payment cards and adjacent applications, today released its financial results for the three and six months ended June 30, 2021.
The first half report, to be filed with Financial Supervisory Authority in Norway (Finanstilsynet), and other materials are accessible on the Company’s website: www.idexbiometrics.com/investors/interim-results/ .
On 12 August, 2021, at 15:00 CET, Vince Graziani, Chief Executive Officer, will conduct a webcast presentation during which he will review results. The webcast presentation can be accessed through: https://channel.royalcast.com/landingpage/hegnarmedia/20210812_2/
Performance Review
For the second quarter ended June 30, 2021, IDEX Biometrics recorded revenue of $697 thousand, compared to $149 thousand for the second quarter of 2020, representing an increase of 368%. Sequentially, revenues increased 12% from first quarter 2021 revenue of $624 thousand.
Total operating expenses for the second quarter of 2021 were $8.1 million, compared to $6.3 million for the second quarter of 2020, representing an increase of 29%. Operating expenses were flat sequentially.
Net loss for the second quarter of 2021 totaled ($7.2 million), representing a loss per share of ($0.01), in contrast to ($6.4 million) for the second quarter of 2020, representing a loss per share of ($0.01), and ($7.5 million) for the first quarter of 2021, representing a loss per share of ($0.01).
The Company incurred an operating cash deficit of ($6.7 million) for the second quarter of 2021, versus ($5.7 million) for the second quarter of 2020 and ($6.9 million) for the first quarter of 2021. The Company’s cash balance totaled $19.3 million as of June 30, 2021, versus $25.9 million as of March 31, 2021.
Commercial and Market Updates
Second quarter 2021 events reflected continued progress toward large-scale smart card deployment with customers and issuers:
- The Company received its first significant production order for its TrustedBio solution from IDEMIA, supporting the launch of IDEMIA’s second-generation F.CODE card earlier in the quarter.
- Activities in Asia, notably China, are resulting in further expansion of the Company’s pipeline of opportunities for near-term revenue, with biometrically-enabled applications in payment cards, multi-use cards (e.g., payment cards also used for electronic ticketing), the rapidly evolving DCEP space, and access control.
The Company continues to enjoy sustained demand from its initial customer for a card-based access control solution for computer networks, addressing the vulnerabilities of password-based credentials with an easy-to-use, cost effective, and highly secure solution based on the Company’s technologies.
Commenting on recent events and performance, Vince Graziani, Chief Executive Officer, stated, “I am pleased to report the Company’s order backlog continued its promising expansion, and I am confident the long-awaited uptake in fingerprint-based card authentication is approaching. In addition, recently announced commercial achievements and the strengthening of the Company’s leadership team are both important factors contributing to my confidence. Notably, IDEX Biometrics and Infineon Technologies AG, on July 15, jointly announced a new reference design for the highest performance smart card with fingerprint authentication. Based on Infineon’s latest secure element microprocessor, specifically optimized for integration of our TrustedBio TM solution, this reference design enables fingerprint-authenticated EMV payment card transactions that are three times faster than currently available solutions.“
Mr. Graziani continued, “Our partners recognize our innovative and highly-differentiated products address the challenges of high costs and unsatisfactory performance head on. TrustedBio’s advantages allow for reduced component count, faster time to market, and lower card manufacturing complexity. TrustedBio integrates a large-area sensor and a powerful, yet small-footprint, ASIC into one device offering image capture, algorithmic processing, power harvesting and management, and encryption. No competitor comes close to providing the performance and economic benefits of TrustedBio.”
For further information contact:
Marianne Bøe, Investor Relations
E-mail: marianne.boe@idexbiometrics.com
Tel: + 47 9180 0186
About IDEX Biometrics
IDEX Biometrics ASA (OSE: IDEX and NASDAQ: IDAF) is a leading provider of a leading provider of advanced fingerprint identification and authentication solutions for payment cards and adjacent applications, offering simple, secure and personal authentication for all. We help people make payments, prove their identity, gain access to information, unlock devices or gain admittance to buildings with the touch of a finger. We invent, engineer, and commercialize these secure, yet incredibly user-friendly solutions. Our total addressable market represents a fast growing multi-billion-unit opportunity.
For more information, visit www.idexbiometrics.com and follow on Twitter @IDEXBiometrics
Trademark Statement
The wordmark ‘IDEX’, the trade name TrustedBio, and the IDEX logo are registered trademarks of IDEX Biometrics ASA. All other brands or product names are the property of their respective holders.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
- FingerMotion is planning to host a corporate update call on August 25 at 1 pm Eastern Time
- As part of the call, FNGR CEO Martin Shen is expected to cover recent developments, including the quarterly financial results, application to uplist to the NASDAQ, and plans for an upcoming annual meeting of shareholders
- A question-and-answer session is scheduled at the end of the call
FingerMotion (OTCQX: FNGR), an evolving technology company with core competency in mobile payment solutions in China, as well as SMS/MMS, will be hosting a corporate update call scheduled for August 25, 2021, at 1 pm Eastern Time. As part of the call, CEO Martin Shen will cover various subjects (https://ibn.fm/PEYuN).
The update is planned against the backdrop of recent positive announcements, including the company’s release of Q1 2021 results, in which it reported record quarterly revenue of $6 million. FingerMotion’s SMS & MMS and Telecommunications Products & Services (“TPS”) notched impressive double-digit and triple-digit revenue growth rates, respectively, compared to Q1 2020. Q1 2021 was also the second consecutive quarter in which the company reported revenue from its Big Data division (https://ibn.fm/2MZxA).
During the update call, these results are expected to take center stage along with the company’s recent application to have shares of its common stock listed on the Nasdaq Capital Market. While there is no guarantee that the submission will be approved, the application still marks a key milestone for the company’s evolution, according to Shen (https://ibn.fm/pQKCc). Shen is expected to talk about this application, as well as the plans for an upcoming annual meeting of shareholders in the near future.
A question-and-answer session, wherein the company will answer questions submitted via emails, is scheduled at the end of the call. More details on this will be provided closer to the day of the call.
Founded in 2016, FingerMotion has evolved over the years. It currently has three operational and revenue-generating business units – TPS, SMS & MMS, and Big Data – with plans to make a fourth division, the rich communication services (“RCS”), operational in due course.
FingerMotion is one of only a few companies in China with access to wholesale rechargeable minutes from China’s largest mobile phone providers that can be resold to consumers. Additionally, earlier this year, buoyed by its big data product dubbed Sapientus, the company forayed into insurtech through its partnership with Pacific Life Re-insurance, which appears to have set the foundation for similar alliances in the insurtech sector.
Since then, FNGR has entered into an agreement with Happy Life Insurance to create an innovative, data-driven insurance business model and also expects additional contracts relating to its insurtech products by the year’s end,
To support its foray into insurtech, FingerMotion recently announced the completion of the first stage of prototyping of its insurtech model and expects completion by the end of 2021 (https://ibn.fm/5GR6B)
For more information, visit the company’s website at www.FingerMotion.com.
NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR
About ChineseWire
ChineseWire (CW) is a specialized communications platform focused on promising China-based companies that are listed in North America. As one of 40+ brands within the InvestorBrandNetwork (“IBN”), CW provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution to IBN’s millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, CW is uniquely positioned to best serve private and public Chinese companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CW brings its clients unparalleled visibility, recognition and brand awareness. CW is where news, content and information converge.
For more information, please visit https://www.ChineseWire.com
Please see full terms of use and disclaimers on the ChineseWire website applicable to all content provided by CW, wherever published or re-published: http://IBN.fm/Disclaimer
ChineseWire (CW)
Los Angeles, California
www.ChineseWire.com
310.299.1717 Office
Editor@ChineseWire.com
ChineseWire is part of the InvestorBrandNetwork.
Flora Growth Corp. (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, today announced acceleration of its transition plans to be compliant with the recently approved Nasdaq board diversity initiatives. As part of this transition, Flora has appointed Lead Scientific Advisor Dr. Annabelle Manalo-Morgan, PhD, to its board of directors, effective immediately. Approved by the SEC on August 6, 2021, Nasdaq’s board diversity rule is a disclosure standard designed to encourage a minimum board diversity objective for companies and provide stakeholders with consistent, comparable disclosures concerning a company’s current board composition. The Flora team shares these fundamental values regarding diversity and takes meaningful action to support social equality, promote inclusiveness and champion each individual’s unique mix of experiences and perspectives. Dr. Annabelle is a scientist, educator, author, mother of five, respected key opinion leader, and a philanthropist and entrepreneur focused on pharmaceutical innovation and clinical trial research in medical cannabis. “We are honored to welcome Dr. Annabelle to our board of directors. Her appointment will be critical to our commitment to cannabinoid research and our future success as we continue navigating complex international markets and building out our global distribution platform,” said Luis Merchan, president and CEO of Flora. “Further, I’d like to applaud the efforts of the Nasdaq exchange in promoting diversity in corporate America and the efforts from the Flora team to quickly develop and execute a strategy to position us as leaders in our industry, as we strive to advance our mission of improving lives around the world through cannabis.”
To view the full press release, visit https://ibn.fm/SL5U5
About Flora Growth Corp.
Flora is a cannabis company that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive. Visit www.FloraGrowth.ca or follow @floragrowthcorp on social for more information.
NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at http://ibn.fm/FLGC
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on psychedelic pharmaceutical therapies, has noted key achievements reached by its wholly owned subsidiary Adelia Therapeutics Inc. Most notably, Adelia has achieved key milestones outlined in the terms of a contribution agreement between Cybin, Cybin Corp., Cybin US Holdings Inc. and previous Adelia shareholders. Consequently, the company announced that, in accordance with the agreement, Class B common shares will be issued to Adelia shareholders to satisfy the $379,021.24 due to them on meeting of the relevant milestones. Those shares are exchangeable for common shares in the capital of Cybin, the announcement noted. Adelia aims to develop medicinal psychedelics with improved dosing efficacy and therapeutic indices to address unmet medical needs. Adelia is focused on developing medicinal psychedelics that offer improved dosing efficacy and therapeutic indices to address unmet medical needs. The company is particularly intent on the development of treatment regimens consisting of proprietary psychedelic molecules and related clinical protocols.
To view the full press release, visit https://ibn.fm/DWLHC
About Cybin Inc.
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at http://ibn.fm/CYBN
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, appears poised for rapid growth as the application space for EEG-based solutions expands. “With its current and future products, including disposable EEG headsets for neurological patients, long-term monitoring solutions, and AI-empowered technology for recording brain activity, the company appears well-placed within the growing brain monitoring space,” reads a recent article. This comes as the brain-computer interface (“BCI”) field is growing rapidly, representing one of the main driving factors behind the expansion of EEG technology. It is a promising approach to overcoming paralysis by decoding brain signals directly from the scalp and translating them into movements of a virtual or robotic effector. This powerful technology can provide opportunities for motor rehabilitation from a number of conditions and even help patients who’ve lost the ability to speak. “Committed to pushing the boundaries of what’s possible in the neurology space, Brain Scientific brings the groundbreaking technology that aims to enable what was inconceivable until recently.”
To view the full article, visit: https://ibn.fm/oiwdT
About Brain Scientific Inc.
Brain Scientific is a commercial-stage health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at http://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021. With two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological and genomics tests. According to Frost & Sullivan, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 41,700 clinical samples as of December 31, 2019. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity. For more information, visit the company’s website at www.anpacbio.com
To view IBN’s virtual coverage of Investor Summit Group’s Q3 Virtual Event, visit https://ibn.fm/2021InvestorSummitQ3
About InvestorBrandNetwork’s Virtual Coverage
The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the publicly traded companies participating virtually at this month’s Investor Summit. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of the event.
For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
LAS VEGAS and VANCOUVER, British Columbia, Aug. 11, 2021 — TAAT ™ GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the “Company” or “TAAT ™ ”) is pleased to announce that it has appointed Peter Nguyen and John Martin to its Board of Directors as independent directors, effective today. Mr. Nguyen and Mr. Martin have also been appointed as audit committee members of the Company. Following their appointments, the Company’s Board of Directors will consist of six directors, four of whom are independent directors as required by leading public stock exchanges. The Company’s audit committee members are all independent directors consisting of John Cumming, John Martin, and Peter Nguyen.
Peter Nguyen is a Chartered Professional Accountant and an alumnus of the University of British Columbia. Mr. Nguyen serves as an officer and director of several publicly traded companies in a variety of industries. Mr. Nguyen has more than 10 years of experience in various financial reporting and business strategy positions and has held several senior financial positions for public and private entities where he provides assurance, corporate financing, tax, and business advisory services.
John Martin has over 35 years of international business experience, mainly in capital markets and fund management. Mr. Martin held senior positions with Royal Bank of Canada and for 10 years was Head of Capital Markets at Bank of Tokyo Mitsubishi (Switzerland). In 2002, he established CMI Credit Market Investments Sarl., an advisory firm active in distressed debt.
The Company’s Board of Directors has been diligently working to institute updated regulatory and compliance procedures with a focus on establishing and maintaining Disclosure Controls and Procedures (“DC&P”), Internal Control over Financial Reporting (“ICFR”), and other corporate governance protocols in accordance with the regulations and standards of leading public stock exchanges. The Company previously announced its application to list its common shares on the Nasdaq Capital Market in a press release dated April 23, 2021.
TAAT™ Chief Executive Officer Setti Coscarella commented, “On behalf of the Company’s Board of Directors, we are pleased to welcome Mr. Nguyen and Mr. Martin to the team, who are each bringing to the table unique expertise in public companies. TAAT™ has made considerable strides in the past year, with public market presences in good standing in Canada, the United States, and Germany. Within just nine months of being publicly listed in Canada, TAAT™ ascended to the OTCQX® Best Market in the United States. Moreover, upon becoming a ‘post-revenue’ company at the end of 2020, TAAT™ was added to the CSE Composite Index® as well as its CSE25™ subset (the 25 largest firms in Composite by market capitalization). We look forward to working with Mr. Nguyen and Mr. Martin as we continue our initiatives to build market share in the USD $814 billion global tobacco industry.”
On behalf of the Board of Directors of the Company,
TAAT ™ GLOBAL ALTERNATIVES INC.
“Setti Coscarella”
Setti Coscarella, CEO and Director
For further information, please contact:
TAAT™ Investor Relations
1-833-TAAT-USA (1-833-822-8872)
investor@taatusa.com
THE CANADIAN SECURITIES EXCHANGE (“CSE”) HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR HAS OR DOES THE CSE’S REGULATION SERVICES PROVIDER.
About TAAT ™ Global Alternatives Inc.
The Company has developed TAAT™, which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in “Original”, “Smooth”, and “Menthol” varieties. TAAT™’s base material is Beyond Tobacco™, a proprietary blend which undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with “Big Tobacco” pedigree, TAAT™ was launched first in the United States in Q4 2020 as the Company seeks to position itself in the $814 billion 1 global tobacco industry.
For more information, please visit http://taatglobal.com .
References
1 British American Tobacco – The Global Market
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking information and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur, or be achieved. Forward-looking information in this news release includes statements regarding the anticipated performance of TAAT™ in the tobacco industry, in addition to the following: Potential outcomes from the addition of two new members to the Company’s Board of Directors, potential outcomes relating to the planned introduction of regulatory and compliance procedures as detailed in the press release. The forward-looking information reflects management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking information. Although the Company believes that the assumptions and factors used in preparing the forward-looking information are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed timeframes or at all. Factors that could cause actual results or events to differ materially from current expectations include: (i) adverse market conditions; (ii) changes to the growth and size of the tobacco markets; and (iii) other factors beyond the control of the Company. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking information. The forward-looking information included in this news release are made as of the date of this news release and the Company expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law.
The statements in this news release have not been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking the Company’s products will vary from person to person. No claims or guarantees can be made as to the effects of the Company’s products on an individual’s health and well-being. The Company’s products are not intended to diagnose, treat, cure, or prevent any disease.
This news release may contain trademarked names of third-party entities (or their respective offerings with trademarked names) typically in reference to (i) relationships had by the Company with such third-party entities as referred to in this release and/or (ii) client/vendor/service provider parties whose relationship with the Company is/are referred to in this release. All rights to such trademarks are reserved by their respective owners or licensees.
Statement Regarding Third-Party Investor Relations Firms
Disclosures relating to investor relations firms retained by TAAT™ Global Alternatives Inc. can be found under the Company’s profile on http://sedar.com .
SRAX (NASDAQ: SRAX) is a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform. In an effort to bridge the gap between listed corporations and investors, the company recently introduced a number of key platform enhancements. “Sequire has recently released new features to help facilitate communication between its listed corporate subscribers and retail investor base, consisting of an automated email feature as well as an SMS function,” reads a recent article. “Sequire’s listed corporate base will have access to custom filters to assist them in structuring campaigns directed at specific investor categories, along with automation triggers, machine learning and other enhancements designed to promote frictionless communication between corporations and the millions of retail investors on their platform. ‘These new tools will allow companies to better manage communication with their shareholder base by defining pre-established triggers that will execute both email and SMS messages,’ said SRAX founder and CEO Christopher Miglino (https://ibn.fm/u0ITG).”
To view the full article, visit https://ibn.fm/3Gory
About SRAX Inc.
SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com and MySequire.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER), the country’s largest independent alkaline water company, today announced that its Alkaline88(R) Deliciously Smooth(TM) water will soon be available in over 400 United Pacific stores throughout the Western United States. According to the update, the move is made possible through WTER’s partnership with Core-Mark, which will be distributing the product from its centers throughout the western region. “United Pacific is a great win for us. Alkaline88 will launch in late August or early September in over 400 United Pacific, Rocket-branded convenience stores. United Pacific is a market leader in California, Oregon, Washington, and Colorado,” said Ricky Wright, president and CEO of The Alkaline Water Company. “The c-store channel remains a focus for us in fiscal 2022. We expect to see a significant increase in volume and revenue from this relationship.”
To view the full press release, visit https://ibn.fm/NRmIE
About The Alkaline Water Company Inc.
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in six unique, all-natural flavors with new flavors coming soon. In 2021, The Alkaline Water Company was pleased to welcome Shaquille O’Neal to its board of advisors and to serve as the celebrity brand ambassador for the Alklaine88 and A88 Infused brands. To purchase Alkaline88 and A88 Flavor Infused products online, visit www.Alkaline88.com. To learn more about the company, visit www.TheAlkalineWaterCo.com.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
- U.S. government infrastructure plans, rising housing demand, seasonal trends pointing to potential 65% increase in lumber prices by end of 2021
- SGTM transforms storm waste into gardening mulch, playground surfacing material, specialty cypress lumber
- Clients include Circle K, The Kroger Company, 7-Eleven, Old Castle Lawn & Garden
- Company completed two-year audit, commenced FORM-10 process in preparation for NASDAQ uplist
Biden’s infrastructure plans, seasonal trends and an expected increase in housing demand are setting the stage for a potential 65% increase in the cost of lumber, according to experts (https://ibn.fm/K3vD5). Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, is positioned to benefit from rising prices through the manufacture of specialty cypress lumber via the company’s sawmill operations.
Lumber prices may have taken a fall from their 2020 peak, but analysts are expecting a sharp rebound by the end of 2021. The nearly $1 trillion bipartisan infrastructure deal, combined with the continued rise of housing prices and seasonal trends, is setting the stage for a massive increase in the cost of lumber according to Joshua Mahony, a senior market analyst at the IG trading platform (https://ibn.fm/K3vD5).
“There is good reasoning behind the idea that the losses we are seeing over recent months could soon enough bring another major buying opportunity for the bulls to come back into dominance,” said Mahony. “That reversal historically results in a bullish reversal to regain lost ground and bring us back into a positive end to the year. This current pullback is in fact part of a seasonal trend that typically resolves in a dramatic recovery towards the end of the year.”
SGTM is poised to benefit from the lumber price rally by providing synergistic and environmentally beneficial solutions to tree and storm waste disposal that have historically created environmental burdens on disposal sites around the country. Rather than allow this natural waste to be directed to landfills, SGTM collects tree biomass and transforms it into playground surfacing material, specialty cypress lumber, and a variety of organic, next-generation mulch products that allow water and air to penetrate the soil and roots — a vital process that promotes plant health and growth.
After concluding a record-breaking year in 2020 with impressive financial results so far in 2021, SGTM continues its expansion plans through a strategy that focuses on organic growth, relationships with strategic partners, and expanded relationships with top global franchises that include Circle K, The Kroger Company, 7-Eleven and Old Castle Lawn & Garden. In addition to completing a two-year audit, the company commenced its FORM-10 process to become fully reporting with future plans to uplist to NASDAQ.
SGTM’s centralized operations are based in Jacksonville, Florida across 26 acres with ample room to expand. With over 40 years of next-level experience with mulch manufacturing and tree management, SGTM’s leadership is committed to sustainably growing the company through a multi-pronged strategy that puts stewardship of the environment at the core of its mission.
To learn more about Sustainable Green Team, please visit www.NationalArborCare.com and view the investor presentation at https://ibn.fm/GBgnK.
NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF), a multistate cannabis operator and house of premium brands, was featured in the “Bell2Bell Podcast,” a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. Red White & Bloom’s CEO and Executive Chair Brad Rogers joined the latest episode to discuss the company’s business model and brand strategy spanning multiple rapidly developing U.S. cannabis markets. “Red White & Bloom (‘RWB’) started off as a beachhead in Michigan; it was a state that was not heavily penetrated whatsoever because of the fact that there were no public companies that were able to own a license in that state at the time,” Rogers said. “We came up with a very unique structure to be able to actually take advantage of the regs and enter that state as an investor into a privately owned company, which we have since gained control over. That was our entry into the market, but what was unique about RWB and RWB brands is the fact that we took a brand strategy to this.”
To view the full press release, visit https://ibn.fm/PUTJe
About Red White & Bloom Brands Inc.
The company is positioning itself to be one of the top three multistate cannabis operators active in the U.S. legal cannabis and hemp sector. RWB is predominantly focusing its investments on the major U.S. markets, including Michigan, Illinois, Massachusetts, Arizona and California with respect to cannabis, and the U.S. and internationally for hemp-based CBD products. For more information about the company, visit www.RedWhiteBloom.com.
NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at http://ibn.fm/RWBYF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has adjourned its Special Meeting of Stockholders. The meeting was convened on Aug. 10, 2021, at 3 p.m. CT, and then adjourned, with a plan to reconvene on Aug. 17, 2021, at 3 p.m. CT. The reason for the adjournment was to solicit more votes on a key proposal. According to the announcement, the proposal in questions calls for approval of an amendment to the company’s certificate of incorporation to increase the number of authorized shares of company common stock to 200 million; the current number of authorized shares of common stock is 100 million. During the meeting, stockholders voted and approved several other proposals, including an amendment to the Amended and Restated 2012 Stock Incentive Plan, the issuance of additional shares of common stock of the company based on a previously approved equity line of credit arrangement; and the ratification of the appointment of Baker Tilly US LLP as POAI’s independent registered public accounting firm for the fiscal year ending December 31, 2021. Before the next scheduled meeting, POAI will solicit proxies from its stockholders. POAI is also encouraging all stockholders who have not yet voted to do so as soon as possible.
To view the full press release, visit https://ibn.fm/5iHcX
About Predictive Oncology Inc.
Predictive Oncology operates through three segments (Skyline, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA (“DNA/RNA”) and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood and irrigation fluid, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information about the company, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
PlantX Life (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) today announced that its wholly owned subsidiary Bloomboxclub Limited, a U.K.-based e-commerce platform that sells and delivers indoor plants, is collaborating with The Walt Disney Company (NYSE: DIS) in the U.K. The partners are teaming up for a campaign to promote Bloombox products and celebrate the release of Disney’s new film, Jungle Cruise, now showing in cinemas and on Disney+ with Premier Access (subscription and additional fee required). As part of the new co-branded campaign, Bloombox will promote the adventure-filled film through the launch of a new Amazonian plant collection, including Jungle Cruise inspired terrariums, a social media campaign and a “Hunt for the Healing Tree” treasure hunt on the Bloombox website. “Bloombox’s collaboration with Disney is truly a momentous opportunity to celebrate plants and their integral role and impact across the film industry,” said PlantX Founder Sean Dollinger. “We are beyond thrilled to have Disney’s support in sharing the Bloombox exotic plant collection with our community.”
To view the full press release, visit https://ibn.fm/vQv1n
About PlantX Life Inc.
As the digital face of the plant-based community, PlantX’s platform is the one-stop shop for everything plant-based. With its fast-growing category verticals, the company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, the company currently has plans underway to expand its product lines to include cosmetics, clothing and its own water brand — but the business is not limited to an e-commerce platform. The company uses its digital platform to build a community of like-minded consumers and, most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs and brands. The company eliminates the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life. For more information, visit the company’s website at https://Investor.PlantX.com.
NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at http://ibn.fm/PLTXF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Nextech AR Solutions (OTCQB: NEXCF) (NEO: NTAR) (CSE: NTAR) (FSE: N29), an emerging leader in augmented reality (“AR”) for eCommerce, AR learning applications, AR-enhanced video conferencing and virtual events, has announced that CEO Evan Gappelberg will be participating in an upcoming virtual event. The special Proactive Investors Livestream will feature a discussion about the Metaverse and Nextech’s recent acquisition of spatial-based computing company ARWAY Ltd. ARWAY founder and CEO Baran Korkmaz will also be a guest speaker during the webinar. ARWAY offers a Unity-based platform that uses AI to scan and recognize surroundings for hyper-accurate, location-based 3D mapping. The company also offers users an Augmented Reality Software Kit (“SDK”) to frame the digital world in a few minutes. According to the announcement, the acquisition provides Nextech with a spatial mapping platform essential to building the Metaverse. The livestream event is scheduled for Aug. 11, 2021, and will start at 12:30 p.m. ET.
To register for the full webinar, visit https://ibn.fm/AvKiw
To view the full press release, visit https://ibn.fm/wW6Nf
About Nextech AR Solutions Corp.
Nextech develops and operates augmented reality (“AR”) platforms that transport three-dimensional (“3D”) product visualizations, human holograms and 360-degree portals to its audiences altering e-commerce, digital advertising, hybrid virtual events (events held in a digital format blended with in-person attendance) and learning and training experiences.
Nextech focuses on developing AR solutions; however, most of the company’s revenues are derived from three e-commerce platforms: vacuumcleanermarket.com (“VCM”), infinitepetlife.com (“IPL”) and Trulyfesupplements.com (“TruLyfe”). VCM and product sales of residential vacuums, supplies and parts, and small home appliances sold on Amazon. For more information about the company, please visit www.NextechAR.com.
NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at http://ibn.fm/NEXCF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
- Clinical study HYPER-H21-1 evaluates the use of patented DehydraTECH(TM)-processed CBD for use against hypertension
- Hypertension is a primary or contributing factor in the death of almost 500,000 people per year, with approximately one in four adults aged 20 to 44 suffering from high blood pressure
- Initial results of the study show that blood pressure was reduced in both male and female volunteers, resulting in the reinforcement of pre-existing findings demonstrating that DehydraTECH delivers superior performance
- Lexaria plans on launching two additional clinical trials, for a total of three clinical trials in 2021 for the DehydraTECH-CBD with hypertension applications
Lexaria (NASDAQ: LEXX), a global innovator of proprietary patented drug delivery platform DehydraTECH(TM), has released partial results from human clinical study HYPER-H21-1. The study evaluates DehydraTECH-processed cannabidiol (“CBD”) for potential application against hypertension (https://cnw.fm/M0xEy).
Hypertension, also referred to as high blood pressure, is a primary or contributing factor in the deaths of almost 500,000 people per year. Hypertension can double the risk of having a heart attack or quadruple the chance of having a stroke. The likelihood of heart failure, vision loss, renal disease, peripheral artery disease, dementia, and more can be attributed to cases of high blood pressure. Statistically, one in four adults aged 20 to 44 has high blood pressure.
The partial results showed that blood pressure was reduced across both male and female volunteers; it was most pronounced with DehydraTECH-CBD in the study’s first 10 to 50 minutes. These results reinforced the pre-existing findings demonstrating that DehydraTECH delivers superior performance over generic CBD controls.
Chris Bunka, CEO of Lexaria, commented on the study, saying, “We are very encouraged by these early results in our 2021 hypertension program. Lexaria’s technology enabled a rapid and sustained drop in blood pressure, especially systolic pressure and particularly in Stage 2 hypertensive volunteers.”
Lexaria’s DehydraTECH technology is designed for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. The method increases the effectiveness and improves the way that active pharmaceutical ingredients enter the bloodstream (like CBD). Benefits of the delivery method include:
- Quicker delivery
- Increase in bioavailability
- Increase in the brain absorption
- Improved drug potency
- Reduced drug administration cost
- Masked unwanted taste
Lexaria has demonstrated these benefits from other animal studies, elevating the quantity of the drug delivered across the blood-brain barrier by as much as 1,900%.
Lexaria was also pleased that the subjects of this human clinical study tolerated the DehydraTECH-CBD, with no serious adverse events or side effects observed or reported. The concentration-matched, generic CBD control ingested resulted in unwanted side effects in some volunteers — primarily gastrointestinal problems, including diarrhea.
Lexaria plans to complete its ongoing additional sample and data analyses work for this study, reporting upon those outcomes when complete. A second human clinical hypertension study, HYPER-H21-2, has completed dosing, with three different doses of DehydraTECH-CBD (150mg per dose), administered evenly over the course of a 24-hour monitoring period.
The company is optimistic that repeated dosing over this sustained period may further enhance efficacy. The results of both studies will be evaluated and considered before the company begins its planned third human clinical hypertension study planned for fall 2021. Lexaria is considering evaluations for a fourth, expanded, randomized, controlled human clinical hypertension trial. The fourth trial will be dependent on the results from the current trials and investigations into a larger population for a more enhanced statistical and clinical significance.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
Cannabidiol, or CBD for short, is one of the chemical compounds found in the cannabis plant. This cannabinoid is all the rage these days and can be found in a huge variety of products including water, sweets, snacks and even your morning cup of coffee. It is also now being included in body care products such as face masks, moisturizers, body lotions and even lip care products. But should you spend your hard-earned money on these products?
While scientific evidence of their benefit is still scant, a number of studies suggest CBD beauty products may offer some benefits. For example, a 2019 study on CBD ointments used to manage the symptoms of individuals that suffered from atopic dermatitis and psoriasis concluded that CBD could be a safe and efficacious remedy for inflammatory skin ailments. This study had 20 participants.
Another clinical trial done in 2020 focusing on people suffering from peripheral neuropathy indicated that there was symptom relief for those who used CBD when compared to the group that got a placebo. This study had 29 subjects.
While those two studies show promise, their sample size was small, and there is no telling what the results may be if the studies are replicated using large-scale samples. Nevertheless, the preliminary studies suggest that some benefits can be obtained by using CBD in body care products.
The next question may have to do with where to buy the best CBD body-care products. The internet is awash with sites selling these products, but caution has to be taken to select a reputable retailer who is selective about the products they sell.
If there is no particular brand of beauty-care product seller that immediately comes to mind with regard to having a reputation for selling quality products, follow the following tips to select a quality CBD beauty product.
First, read the certificate of analysis (“COA”). This is a lab test report provided by an independent firm. The report details the ingredients and their quantities in a given product. The report also shows what contaminants, if any, are present in the product. Contaminants worth noting include pesticides, heavy metals and mold.
Take note of the potency. The potency of CBD is normally indicated in milligrams. The higher the number, the more potent the product. More isn’t necessarily better as product use requirements differ.
Pay attention to the CBD type. Some products will be made from CBD isolate (pure CBD without any other cannabis compound), full-spectrum CBD (CBD containing other cannabis compounds such as flavonoids, terpenes and THC within the legal limit of 0.3%) and broad-spectrum CBD, which has all other cannabis compounds except THC. Full-spectrum products are said to offer an entourage effect and better results, but you can buy broad-spectrum or isolate CBD products if you have concerns about being tested for drugs.
All in all, it pays to source your products from established suppliers or manufacturers such as Flora Growth Corp. (NASDAQ: FLGC) so that you don’t risk your money on products from questionable sources.
NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
Ideanomics (NASDAQ: IDEX), a global company focused on the convergence of financial services and industries experiencing technological disruption, is leveraging an innovative business model to capitalize on growth opportunities. “With its three strong pillars of EV (vehicles, charging and energy), IDEX is shaping the future of energy-driven commercial fleets through its two divisions, Ideanomics Mobility and Ideanomics Capital,” reads a recent article. The piece goes on to discuss the company’s focus on innovation through its business operations. These include US Hybrid, which specializes in the design and manufacturing of zero emission powertrain components for electric, hybrid, and fuel cell medium and heavy-duty municipality vehicles, commercial trucks, buses, and specialty vehicles throughout the world. Secondly, WAVE “powers the largest electric mass transit bus fleet in the U.S, at the Antelope Valley Transportation Authority north of Los Angeles with its wireless inductive charging pads.” Further, the article discusses Solectrac. “Ideanomic’s acquisition of this California-based facility reflects the company’s visionary approach towards the electric tractor revolution. This is a pioneering move benefitting farmers and crops, as EV solutions are still unheard of in this segment, while also grabbing a growing slice of agricultural market revenue.”
To view the full article, visit https://ibn.fm/j3zSj
About Ideanomics Inc.
Ideanomics is a global company focused on the convergence of financial services and industries experiencing technological disruption. The Ideanomics Mobility division is a service provider that facilitates the adoption of electric vehicles by commercial fleet operators through offering vehicle procurement, finance and leasing, and energy management solutions under an innovative sales-to-financing-to-charging (“S2F2C”) business model. Ideanomics Capital is focused on disruptive fintech solutions for the financial services industry. Together, Ideanomics Mobility and Ideanomics Capital provide global customers and partners with leading technologies and services designed to improve transparency, efficiency and accountability, and shareholders with the opportunity to participate in high-potential growth industries. For more information, visit www.Ideanomics.com.
NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at http://ibn.fm/IDEX
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
The European Commission, which is the regulatory arm of the European Union (“EU”), has modified the regional block’s energy law with an aim of setting targets for the use of sustainable forms of energy in the heating, cooling and transportation sectors. The new plan mandates member states to reduce the emissions from new vans and cars by 65% before the end of 2035 when compared to the levels of emissions registered in 2021. Thereafter, countries are expected to cut emissions by 100 percent in comparison to the levels of 2021.
The enhanced emissions law also came with additional rules asking governments to ramp up the establishment of EV charging infrastructure. Additionally, the plan sets out suggestions to increase the proportion of renewable energy in the EU block from 32%, which it is currently, to 40% by 2030.
This law can be looked at as a model by other jurisdictions that would like to reduce their carbon emissions and also bolster investment into the industries crucial to bringing new innovations in the green energy sector.
The U.S. Energy Information Administration (“EIA”) recently reported that there was a significant increase in large-capacity solar installations, and the agency projected that solar would soon exceed the penetration of wind energy in 2022, something that had never happened before. The EIA also projects that solar as well as wind energy capacity in the country would grow to 15% of all the energy generated within the United States. Currently, wind and solar account for just 11% as per the records for 2020. The EIA forecasts that 17GW of solar energy will be brought on line this year while wind will add just 6GW of energy in 2021.
The trend of renewable energy growth isn’t in the U.S. alone. Statistics indicate that globally, the amounts of green energy generated in 2020 exceeded that generated in 2019. This growth occurred as a reduction and was observed in the amount of natural gas, coal and oil used to generate electricity in different jurisdictions.
The growing uptake of renewable energy, especially with the enactment of enabling laws in major regions, such as the EU, the U.S. and other major world powers, is likely to boost the demand for the minerals extracted and marketed by firms such as Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) since those metals will be needed to manufacture electric vehicles, establish wind and solar farms, as well as set up the associated infrastructure.
NOTE TO INVESTORS: The latest news and updates relating to Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) are available in the company’s newsroom at https://ibn.fm/EXN
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com
MiningNewsWire is part of the InvestorBrandNetwork.
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“ HempFusion ” or the “ Company ”), a leading health and wellness company offering premium probiotic supplements and products containing CBD, announced today it will report its financial results for the second quarter ended June 30, 2021 at 8:00 a.m. (Eastern Time) on Monday, August 16, 2021 followed by an 8:30 a.m. (Eastern Time), conference call and webcast with a question-and-answer session.
To participate in the call, please dial 888-506-0062. For international callers, please dial 973-528-0011. Use Entry Code: 746381.
To join the webcast, please visit https://www.webcaster4.com/Webcast/Page/2710/42495
A replay will be available from the Investor Relations section of HempFusion’s website at HempFusion.com/corporate-information .
ABOUT HEMPFUSION
HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retail locations across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 48 SKUs including tinctures, proprietary FDA Drug Listed Over-The-Counter (OTC) Topicals, Doctor/Practitioner Lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion’s wholly-owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex™ and are available in-store or by visiting HempFusion online at www.hempfusion.com or www.probulin.com .
Follow HempFusion on Twitter , Facebook and Instagram and Probulin on Twitter , Facebook and Instagram .
Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210811005224/en/
Jason Mitchell, N.D.
Chief Executive Officer and Director
Email: ir@hempfusion.com
Phone: 416-803-5638
A scientist at EPFL (the Swiss Federal Institute for Technology) has discovered that it is possible to detect declining cognitive function by using the fingerprints of an individual’s brain. Brain fingerprints refer to the neural connections’ map as detected by brain imaging techniques.
The scientist stumbled upon this discovery after noticing that the brain fingerprints in individuals suffering from cognitive decline are more difficult to detect compared to how easily the brain fingerprints of healthy subjects can be detected.
Just as is the case with fingers, the brain of each individual has a unique pattern that is embedded within it, so no two individuals can have an identical brain fingerprint. As brain imaging has improved, the scientific community has noticed that the different activities that take place within brains cause networks of neural activity to form, and these imprinted networks differ from one person to another.
Dr. Enrico Amico, a scientist at the neuroprosthetics center at EPFL, worked with researchers at Naples-based Parthenope University and the University of Aix-Marseilles. This team studied two groups of people. One group was healthy and didn’t have any cognitive impairment while the second group was composed of individuals who had mild forms of cognitive decline that hadn’t reached the level of being clinically described as dementia.
When the scientists took a close look at the brain fingerprints of these two groups, it was found that the fingerprints of the healthy individuals were easy to identify while it was difficult to identify those of the people who displayed symptoms of cognitive decline. Amico explains that the researchers recorded the electromagnetic brain activity for each individual by taking measurements of the magnetic fields created as neurons fired. This provided a snapshot for each participant’s brain activity.
In addition to having brain fingerprints that were difficult to identify, study participants who had mild cognitive decline also had lower MMSE scores, an assessment often used to diagnose patients who are suspected to be suffering from dementia.
The team also found that the difficulty of identifying brain maps wasn’t restricted to one or a few regions of the brain. The problem was evident in all regions of the brain, indicating that as cognitive function declines, so does other brain activity.
The researchers hope that their findings will trigger interest into further inquiry of the potential of brain fingerprints as a tool to detect the onset of dementia before a person exhibits symptoms. In this way, early intervention could delay the progression of the disease.
If the use of brain fingerprints becomes available as an approved diagnostic tool, it will be an addition to other novel neuro-diagnostic tools such as the disposable EEG headsets manufactured by Brain Scientific Inc. (OTCQB: BRSF), which have been introduced to transform the way physicians and other professionals conduct neurology imaging tests.
NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is focused on early cancer screening and detection. With an aim of changing the way people approach cancer screening, the company develops, distributes and deploys accessible early disease detection devices. “AnPac Bio-Medical is a highly innovative company and an early thought leader and developer of multi-cancer screening technology, which is gaining significant acceptance,” reads a recent article discussing the company. “Cancer Differentiation Analysis (‘CDA’) is AnPac Bio-Medical’s approach to detecting cancer and pre-cancerous diseases. CDA uses the natural biophysical properties of blood and cellular proteins to discover cancerous environments before the tumors even form. CDA technology combines an assessment of existing biomarkers with the biophysical properties and cellular proteins that signal the lead-up to serious health conditions and cancer. It is also used to pinpoint where cancer is most likely located and predict where the risk is highest in the future — all through a standard blood test, at a competitive price point.”
To view the full article, visit: https://ibn.fm/m20YK
About AnPac Bio-Medical Science Co. Ltd.
AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021. With two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. According to Frost & Sullivan, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 41,700 clinical samples as of December 31, 2019. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity. For more information, visit www.AnPacBio.com.
NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at http://ibn.fm/ANPC
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- Red White & Bloom released its Q4 2020 and FY 2020 results and later reported its Q1 2021 results
- In its Q4 2020 results, the company posted a 158% quarter-over-quarter increase in revenue from $CA6.1 million in Q3 2020 to $15.7 million
- Its FY revenue grew from nil in 2019 to CA$23.3 million in 2020, while its gross profit was CA$13.35 million in 2020 from nil in 2019
- RWB reported $32.7 million in Q1 2021 adjusted sales, an increase of 14.5% over Q4 2020
In a statement contained in the company’s December 2020 investor deck presentation, Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) CEO Brad Rogers observed that multiple deals, “judiciously purchased and diligently structured,” were all coming together to create “the most exciting times in the history of the company.” He further noted that the company was looking to build on its key assets focusing on growing the bottom line for its shareholders (https://cnw.fm/kjuF0).
Red White & Bloom recently made two announcements that show its progress thus far and perhaps tell of the dawn of the exciting times. On July 22, the company announced its Q4 2020 and full-year results (https://cnw.fm/Pt9xt).
RWB reported a 158% quarter-over-quarter increase in revenue from CA$6.1 million in Q3 2020 to CA$15.7 million in Q4 2020. The company attributes this increase to the impact of the acquisition the Platinum Premium Cannabis Products (“PV”) on its balance sheet, given that Q4 2020 was the first full quarter post-closing. RWB’s revenue for the year ended December 31, 2020, grew to CA$23.3 million from nil in 2019, while its gross profit for the FY 2020 was CA$13.35 million, or 57% of the FY revenue, compared to nil in 2019.
Red White & Bloom closed FY 2020 having made significant strides as it seeks to be the superior and most recognizable cannabis company in the United States. It completed two transformative acquisitions: PV, which is licensed in California and has products being sold in Oklahoma and Michigan, and Mid-American Growers (“MAG”), a company that owns a 3.6-million-square-foot, state-of-the-art technology and science facility that will enable RWB to attain premium value for the products it wishes to cultivate.
The company has also raised more than US$110 million since January 1, 2020, which it expects will support its expansion and operations. Additionally, as of July 2, 2021, it had about CA$41 million cash on hand.
The company reports adjusted sales for the 1st quarter of $32.7 million, a sequential increase of 14.5% from the prior quarter’s adjusted sales of $28.6 million in Q4 2020. The increase was reduced by the strengthening Canadian dollar and would have been about $1 million higher using a constant dollar comparison (https://cnw.fm/BljZA).
“This was another great quarter for the company as we continued to see strong traction for our brands,” said Brad. “We are building on that momentum and working towards finalizing our revised asset purchase of our Michigan investee to bring their revenue, as well as adjusted sales into IFRS revenue format before the end of this current quarter.”
Once this is complete and the expansion of its Florida operations starts bearing fruits, the company expects to finally report in its quarterly results the strength of its accomplishments so far. As such, more is still to come for Vancouver-based Red White & Bloom as it positions itself to be one of the top three multi-state operators in the United States in cannabis and hemp-derived product lines.
For more information, visit the company’s website at www.RedWhiteBloom.com.
NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://cnw.fm/RWBYF
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
Earlier in June, Andries Rossouw of PwC Africa Mining released a statement noting that during the peak of the coronavirus pandemic, mining companies with higher environmental, social and governance (“ESG”) ratings surpassed the broader market to deliver a 34% average total shareholder return, which is 10 points higher than the general market index. Companies with higher ESG ratings are showing stronger long-term performance in market and shareholder value, as they continue to attract premiums on low-carbon inputs and benefit from capital access at lower interest rates.
This data was obtained from the annual review of the top-40 mining companies compiled by PwC, which examines the global trends in the mining industry. The review includes companies such as Gold Fields, AngloGold Ashanti, Impala Platinum, Sibanye Stillwater and Anglo American.
In the presentation, Rossouw also revealed that market capitalization rose by almost two-thirds to $1.46 trillion, while cash on hand increased by 40% and net profit in the sector grew by 15%.
Copper was found to be the exceptional performer in the metals group, as it contributed about $120 billion to group revenue. The average price of copper is expected to grow by 40% this year, based on consensus data. Additionally, the demand for iron ore is expected to grow, aided by national infrastructure initiatives whose objective is to help economies recover from the impact of the coronavirus.
Forecasts also indicate that the top-40 firms will report the second-highest net profit and record-high earnings and revenue before amortization, depreciation and taxes. This is in addition to showing that the demand for the minerals used in clean-energy technologies will increase sixfold in the next 20 years. In his conclusion, Rossouw notes that it is clear that investors focused on the sector will continue to be drawn to firms that actively embrace ESG policies.
The same can be said for tax transparency, which is an important ESG metric. It affords mining companies the chance to call attention to their significant financial contributions to their communities and the improvements in quality of life, infrastructure and education. Suppliers, governments, communities, employees and customers all expect companies to create sustainable value, which is why mining organizations should embrace tax transparency as part of their ESG strategy. This approach will help support the mining sector and encourage it to be more transparent about the rents and taxes they pay as well as the social benefits their contributions deliver.
For companies such as Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) that are operating in the global uranium extraction segment, adherence to ESG standards is even more important given the specialized applications in which uranium is put to use.
NOTE TO INVESTORS: The latest news and updates relating to Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) are available in the company’s newsroom at http://ibn.fm/UUUU
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com
MiningNewsWire is part of the InvestorBrandNetwork.
The Alkaline Water Company Inc. (NASDAQ:WTER) traded at a new 52-week high today of $2.34. Approximately 920,000 shares have changed hands today, as compared to an average 30-day volume of 3 million shares.
Over the past year, The Alkaline Water Company Inc. has traded in a range of $0.93 to $2.34 and is now at $2.25, 142% above that low.
The Alkaline Water Company Inc. (NASDAQ:WTER) defies analysts with a current price ($2.25) 0.0% above its average consensus price target of $2.25.
Alkaline Water Co Inc is engaged in the business of distributing and marketing bottled alkaline water for retail consumers in different sizes. The firm sells its product in 500ml, 700ml, 1-liter, 1.5-liter 3-liter, and 1-gallon sizes. Its only operating geographical segment being the United States of America. The company sells its product to convenience stores, natural food products stores, large ethnic markets, and national retailers.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
Scientists from the Cancer Research UK Cambridge Institute have designed tests that can detect the presence of a type of brain tumor known as a glioma via a patient’s blood plasma or urine. The group notes that this test is the first of its kind globally, adding that its results, which only included a handful of patients, are promising. The research is currently in its early stages and was published in “EMBO Molecular Medicine.”
Brain tumor recurrence in individuals who have already had a brain tumor removed is high, which is why monitoring patients using an MRI scan is important. Often, physicians also conduct biopsies in addition to performing the scan.
Blood tests that help detect various types of cancer have been a major focus for researchers around the globe. These tests are primarily based on identifying cell-free DNA, which is mutated DNA that is shed by tumor cells when they perish. However, the detection of brain tumor cell-free DNA in the blood has been challenging because of the blood-brain barrier.
This barrier separates blood from the cerebrospinal fluid (“CSF”), which surrounds the spinal cord and brain, hindering the passage of cells and particles like cell-free DNA. This is why the researchers, led by Dr. Richard Mair of the University of Cambridge and Dr. Florent Mouliere of the Rosenfeld Lab at the Cambridge institute, helped develop a pair of approaches that could be used to overcome the difficulties of detecting brain tumor cell-free DNA.
The first of the two approaches works for patients who have undergone brain tumor removal and biopsy. The researchers developed a tumor-guided sequencing test whose purpose was to identify mutations found in the tumor tissue in the patient’s blood plasma, cerebrospinal fluid and urine.
For this approach, the researchers discovered that it was possible to identify mutations even in minute amounts of cell-free DNA in the urine and blood plasma. Of the eight patients who were studied under this approach, the researchers were able to detect cell-free DNA in their urine, blood plasma and cerebrospinal fluid samples.
The second approach involved the scientists looking for other patterns in cell-free DNA that could indicate a tumor’s presence, without identifying the mutations. For this approach, they conducted an analysis of samples obtained from 26 healthy individuals, 27 patients with nonmalignant brain conditions and 35 glioma patients.
Using genome sequencing, they discovered fragments of cell-free DNA in both urine and blood samples, noting that the fragments that came from brain tumor patients were different in size in comparison with those from patients who didn’t have tumors.
The scientists propose that in the future, these tests could be used to monitor patients who have a high risk of brain tumors; this method would be more convenient in comparison to undergoing an MRI every three months, which is the current monitoring method.
As screening and testing for brain cancers is being improved, so are advancements being made in the quest to improve treatment. For example, CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is developing organ-targeted therapeutics that, once approved, will offer better clinical outcomes to patients.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.